-

CRNC Stock Investigation: Robbins LLP Investigates Cerence Inc. (CRNC) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Cerence Inc. (NASDAQ: CRNC) and its officers and directors to determine if they breached their fiduciary duties and violated securities laws. Cerence builds artificial intelligence-powered virtual assistants primarily for the automotive market.

If you would like more information about our investigation of Cerence Inc.'s misconduct, click here.

What Is This Case About: According to a class action complaint filed against Cerence, between February 8, 2021 and February 4, 2022, defendants failed to disclose that: (1) the global semiconductor shortage had a materially negative impact on demand for Cerence's software licenses; and (2) defendants masked the impact of the semiconductor shortage on demand for the Company's software licenses by pulling forward sales. As a result, defendants' statements about Cerence's business, operations, and prospects were false and misleading.

On February 7, 2022, Cerence announced its financial results for the fiscal first quarter of 2022, providing "a 9% decrease at the midpoint compared to the initial FY22 guidance provided on November 22, 2021, and a 3% decrease at the mid-point compared to last year's actual revenue of $387 million." Further, the Company announced it was "withdrawing the fiscal [20]24 target model previously provided…" In response, the price of Cerence stock dropped more than 30%, from a closing price of $63.58 on February 4, 2022, to a closing price of $43.61 per share on February 7, 2022.

Next Steps: If you acquired shares of Cerence Inc. (CRNC) between February 8, 2021 and February 4, 2022, you have legal options. Contact us for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Cerence Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:CRNC

Release Summary
CRNC Stock Investigation: Robbins LLP Investigates Cerence Inc. (CRNC) on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

CPNG Class Action Alert: Robbins LLP Reminds Investors with Losses in Coupang, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coupang, Inc. (NYSE: CPNG) securities between April 6, 2025 and December 16, 2025. Coupang describes itself as one of the fastest-growing technology and commerce companies in the world, providing retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Cou...

Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Beyond Meat, Inc. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Beyond Meat, Inc. (NASDAQ: BYND) securities between February 27, 2025 and November 11, 2025. Beyond Meat operates in the food industry, developing, manufacturing, marketing, and selling plant-based meat products under the "Beyond" brand name in the U.S. and internationally. For more information, submit a form, email attorney Aaron Dumas, Jr.,...
Back to Newsroom